The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.

Interview: Promoting precision medicine using data science 

January 23, 2018

 News Medical interviewed Dr. Rajat Mukherjee, Statistician, and Director of Data Science at Cytel to investigate the potential of data science in clinical development.

Read More

Quantitative Pharmacology & Pharmacometrics for Biomarker Driven Clinical Strategy

November 3, 2015

QPP (sometimes called QP2) remains at the heart of model based drug development. Short for Quantitative Pharmacology & Pharmacometrics, it refers to several types of quantitative modeling including meta-analysis, PK/PD , statistical modeling and the modeling of go-no-go decision rules.

Read More

2 Methods for Evaluating Biomarker Subpopulations in (Adaptive Enrichment) Time to Event Trials

October 5, 2015

One consideration every sponsor of a biomarker-stratified confirmatory trial must take into account, is whether to evaluate the biomarker subpopulation (S) against the rest of the population (S') or against the full population (F).

Mathematically, one would think this makes very little difference as F is partitioned into S and S'. If the null hypothesis is rejected for both S and S' then clearly it is rejected for F too. Similarly, if it is rejected for S and not for S' then the therapy is effective for the biomarker subpopulation, and ineffective for the rest of the population.

As it turns out, whether or not a given biomarker is indeed a predictive biomarker should affect the choice of statistical methodology in time-to-event trials.

Read More